-
CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments
•
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140 million (USD 20.3 million) in the establishment of a private equity fund with a total value of RMB 500 million (USD 72.5 million). The fund will focus on investments in vaccine companies, highlighting CanSino’s commitment…
